WHO to inspect sites performing dissolution studies for biowaivers
This article was originally published in SRA
Executive Summary
The World Health Organization, under its pre-qualification of medicines programme, has announced plans to start inspecting sites that carry out comparative dissolution studies on behalf of pharmaceutical companies to support their requests for biowaivers, ie exemption from performing clinical bioequivalence studies1,2.